The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase II trial of RRx-001 in previously treated SCLC.
 
Daniel Morgensztern
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; PharmaMar; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Merck (Inst); Newlink Genetics (Inst)
 
Michal G. Rose
No Relationships to Disclose
 
John Charles Morris
Speakers' Bureau - Boehringer Ingelheim; Merck
Patents, Royalties, Other Intellectual Property - National Institutes of Health patent
 
Patrick C. Ma
Stock and Other Ownership Interests - Cymeta Biopharmaceutical
Consulting or Advisory Role - Apollomics; AstraZeneca; Takeda
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Takeda
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cymeta Biopharmaceutical (Inst); EpicentRx (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); OncoMed (Inst); Pfizer (Inst); Tesaro (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Christina E. Brzezniak
Research Funding - EpicentRx; Genentech; Xcovery
 
Karen Grace Zeman
No Relationships to Disclose
 
Arvinda Padmanabhan
Speakers' Bureau - Clovis Oncology (I); Roche (I)
 
JoAnn Hirth
No Relationships to Disclose
 
Alexander I. Spira
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck
Consulting or Advisory Role - Array BioPharma (Inst)
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Ellice Yuen-Ming Wong
No Relationships to Disclose
 
Sukhmani Kaur Padda
Consulting or Advisory Role - Abbvie; AstraZeneca; G1 Therapeutics; Janssen
Research Funding - Bayer (Inst); EpicentRx (Inst); Forty Seven (Inst)
 
Saiama Naheed Waqar
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Stem CentRx (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)